摘要
目的:旨在从分子水平探讨p16基因在胰腺组织中缺失突变和蛋白表达情况及其与临床病理的联系。方法:利用免疫组织化学染色ABC法及聚合酶链反应-单链构象多态性(PCR-SSCP)分析技术分别检测29例胰腺良性组织和54例胰腺癌组织中p16蛋白表达和基因缺失突变情况。结果:正常胰腺及良性病变组织中p16蛋白表达率为75.86％,显著高于胰腺癌组织p16蛋白表达率(40.74％)(P<0.005),临床分期中Ⅰ、Ⅱ期p16蛋白表达率(68.18％)高于Ⅲ、Ⅳ期病例(21.88％)(P<0.05)。p16基因缺失突变率良性组织(10.34％)低于胰腺癌组织(42.59％)(P<0.005)。Ⅰ、Ⅱ期癌组织(18.18％)低于Ⅲ、Ⅳ期癌组织(59.38％)(P<0.05)。在胰腺癌不同病理类型及不同组织学分化程度中p16蛋白表达和基因缺失突变无明显差别。结论:p16基因缺失突变和蛋白表达的检测可作为胰腺癌预后评定的一个分子生物学指标。
Objective: To investigate the deletions or mutations and protein ex pression of p16 antioncogene and its
relationship with clinical pathology at molecular level in pancreatic tissue. Methods:29 cases of benign pancreatic tissue
and 54 cases of pancreatic carcinoma were analyzed for genetic deletions or mutations and protein expression of p16 by
immunohistochemical staining and polymerase chain reaction-single stranded co nformation polymorphism (PCR-SSCP)
respectively. Results:The frequency of p16 prot ein expression in normal and benign tissue(75.86% )was markedly high-
er than that in pancreatic carcinoma(40.74% ) (P<0.005). The expression o f p16 protein in Ⅰ and Ⅱ stages (68.18%)
in pancreatic carcinoma was higher than that in Ⅲ and Ⅳ stages(21.88%) (P<0. 05). The deletion or mut ation rate of
p16 in benign tissue (10.34%) was lower than that in pancreatic car cinoma(42.59% ) (P<0.005). In pancreatic cancer,
the frequency of deletions and mutations of p16 in Ⅰ and Ⅱ stages (18.18%)was lower than that in Ⅲ and Ⅳ stages
(59.38%) (P<0.05). In addition,no correlati on was found between the deletions or mutations and expression of p16
and variou s pathological types or histodifferentiation. Conclusion:The detection of the d eletions or mutations and ex-
pression of p16 could be regarded as a molecular biolo gical parameter for the prognosis of patients with pancreatic carci-
noma.
出处
《中国误诊学杂志》
CAS
2004年第6期827-829,共3页
Chinese Journal of Misdiagnostics
